A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
A Randomized, Double-Blinded, Placebo-Controlled Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in Subjects With Decompensated CHF
Sponsor: Scios, Inc.
A PHASE3 clinical study on Heart Decompensation and Heart Failure, Congestive, this trial is completed. The trial is conducted by Scios, Inc. and has accumulated 5 data snapshots since 1996. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Oct 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Scios, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.